Back to search

Peptide record

TPDB26515

Antibacterial Antifungal standard
44 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB26515
Antibacterial Antifungal
Anti-infective peptides
Peptipedia Antifungipept
standard
No
A 44-aa standard-residue multi-activity (Antibacterial and Antifungal) peptide sequence curated from Peptipedia and Antifungipept, with an available 3D structural model.
Sequence
WGCVCSGSTAVANSHNAGPAYCVGYCGNNGVVTRNANANVAKTA
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C179H278N58O60S4
DEQILMF
A
4330.77
8.30
3
0
17
+2
0.86
0.034
57.73
Mammalian: 2.8 hour Yeast: 3 min E.coli: 2 min
8730
2.02
19
Residue Composition
number
8
A
1
R
7
N
0
D
4
C
0
E
0
Q
6
G
1
H
0
I
0
L
1
K
0
M
0
F
1
P
3
S
3
T
1
W
2
Y
6
V
Amino Acid Distribution
A: 8 R: 1 N: 7 D: 0 C: 4 E: 0 Q: 0 G: 6 H: 1 I: 0 L: 0 K: 1 M: 0 F: 0 P: 1 S: 3 T: 3 W: 1 Y: 2 V: 6
Chemical Descriptors
44 reviewed residue count
C179H278N58O60S4 sequence-only estimate (linear, free termini)
4330.77 sequence-only estimate (linear, free termini)
8.30 sequence-only estimate (linear, free termini)
+2 sequence-only estimate (linear, free termini)
0.86 sequence-only estimate (linear, free termini)
0.034 sequence-only estimate (linear, free termini)
Evidence Records 12 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.3-0.6 µM

Target

Clostridioides difficile

Source & Reference

NA

Other

d clinical strains of bacteria: C. perfringens (MIC 0.4-0.8 uM against clinical strains), C. difficile (MIC 0.3-0.6 uM), L. monocytogenes (MIC 0.8 uM), B. cereus (MIC MIC 1.2-1.6 uM), S. pneumoniae (MIC 0.3-0.
Evidence 2 Activity

Activity

MIC
Antibacterial
0.8 µM

Target

L. monocytogenes

Source & Reference

NA

Other

C. perfringens (MIC 0.4-0.8 uM against clinical strains), C. difficile (MIC 0.3-0.6 uM), L. monocytogenes (MIC 0.8 uM), B. cereus (MIC MIC 1.2-1.6 uM), S. pneumoniae (MIC 0.3-0.6 uM), E. faecalis (MIC 2.5 uM)
Evidence 3 Activity

Activity

MIC
Antibacterial
0.3-0.6 µM

Target

S. pneumoniae

Source & Reference

NA

Other

ifficile (MIC 0.3-0.6 uM), L. monocytogenes (MIC 0.8 uM), B. cereus (MIC MIC 1.2-1.6 uM), S. pneumoniae (MIC 0.3-0.6 uM), E. faecalis (MIC 2.5 uM), and E. faecium (MIC 1.2 uM) (data from the 2020 structural pap
Evidence 4 Activity

Activity

MIC
Antibacterial
2.5 µM

Target

Enterococcus faecalis

Source & Reference

NA

Other

nocytogenes (MIC 0.8 uM), B. cereus (MIC MIC 1.2-1.6 uM), S. pneumoniae (MIC 0.3-0.6 uM), E. faecalis (MIC 2.5 uM), and E. faecium (MIC 1.2 uM) (data from the 2020 structural paper below). Also B. subtili
Evidence 5 Activity

Activity

MIC
Antibacterial
1.2 µM

Target

E. faecium

Source & Reference

NA

Other

ereus (MIC MIC 1.2-1.6 uM), S. pneumoniae (MIC 0.3-0.6 uM), E. faecalis (MIC 2.5 uM), and E. faecium (MIC 1.2 uM) (data from the 2020 structural paper below). Also B. subtilis (MIC 6 uM).
Evidence 6 Activity

Activity

MIC
Antibacterial
6 µM

Target

B. subtilis

Source & Reference

NA

Other

IC 2.5 uM), and E. faecium (MIC 1.2 uM) (data from the 2020 structural paper below). Also B. subtilis (MIC 6 uM).
Evidence 7 Activity

Activity

MIC
Antifungal
0.3-0.6 µM

Target

Clostridioides difficile

Source & Reference

Antifungipept

Other

d clinical strains of bacteria: C. perfringens (MIC 0.4-0.8 uM against clinical strains), C. difficile (MIC 0.3-0.6 uM), L. monocytogenes (MIC 0.8 uM), B. cereus (MIC MIC 1.2-1.6 uM), S. pneumoniae (MIC 0.3-0.
Evidence 8 Activity

Activity

MIC
Antifungal
0.8 µM

Target

L. monocytogenes

Source & Reference

Antifungipept

Other

C. perfringens (MIC 0.4-0.8 uM against clinical strains), C. difficile (MIC 0.3-0.6 uM), L. monocytogenes (MIC 0.8 uM), B. cereus (MIC MIC 1.2-1.6 uM), S. pneumoniae (MIC 0.3-0.6 uM), E. faecalis (MIC 2.5 uM)
Evidence 9 Activity

Activity

MIC
Antifungal
0.3-0.6 µM

Target

S. pneumoniae

Source & Reference

Antifungipept

Other

ifficile (MIC 0.3-0.6 uM), L. monocytogenes (MIC 0.8 uM), B. cereus (MIC MIC 1.2-1.6 uM), S. pneumoniae (MIC 0.3-0.6 uM), E. faecalis (MIC 2.5 uM), and E. faecium (MIC 1.2 uM) (data from the 2020 structural pap
Evidence 10 Activity

Activity

MIC
Antifungal
2.5 µM

Target

Enterococcus faecalis

Source & Reference

Antifungipept

Other

nocytogenes (MIC 0.8 uM), B. cereus (MIC MIC 1.2-1.6 uM), S. pneumoniae (MIC 0.3-0.6 uM), E. faecalis (MIC 2.5 uM), and E. faecium (MIC 1.2 uM) (data from the 2020 structural paper below). Also B. subtili
Evidence 11 Activity

Activity

MIC
Antifungal
1.2 µM

Target

E. faecium

Source & Reference

Antifungipept

Other

ereus (MIC MIC 1.2-1.6 uM), S. pneumoniae (MIC 0.3-0.6 uM), E. faecalis (MIC 2.5 uM), and E. faecium (MIC 1.2 uM) (data from the 2020 structural paper below). Also B. subtilis (MIC 6 uM).
Evidence 12 Activity

Activity

MIC
Antifungal
6 µM

Target

B. subtilis

Source & Reference

Antifungipept

Other

IC 2.5 uM), and E. faecium (MIC 1.2 uM) (data from the 2020 structural paper below). Also B. subtilis (MIC 6 uM).